CEO Sofie Qiao told BioWorld Asia that Vivace Therapeutics Inc. can "probably get into the clinic in the next couple of years" with its lead program – an inhibitor that operates in the Hippo-YAP signaling pathway – thanks to $25 million raised in a series B round. The money supplements $15 million garnered by way of the series A financing in 2015, when the San Mateo, Calif.-based firm was founded.